These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 8767284)

  • 1. [A new pharmaceutical concept for the therapy of oropharyngeal and esophageal candidiasis with fluconazole].
    Wildfeuer A; Laufen H; Yeates RA; Zimmermann T
    Mycoses; 1996; 39 Suppl 1():123-6. PubMed ID: 8767284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new pharmaceutical concept for the treatment of oropharyngeal and oesophageal candidosis with fluconazole.
    Wildfeuer A; Laufen H; Yeates RA; Zimmermann T
    Mycoses; 1996; 39(9-10):357-60. PubMed ID: 9009658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Salivary concentrations of ketoconazole and fluconazole: implications for drug efficacy in oropharyngeal and esophageal candidiasis.
    Force RW; Nahata MC
    Ann Pharmacother; 1995 Jan; 29(1):10-5. PubMed ID: 7711339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic optimization of the treatment of oral candidiasis with fluconazole: studies with a suspension.
    Laufen H; Yeates RA; Zimmermann T; de los Reyes C
    Drugs Exp Clin Res; 1995; 21(1):23-8. PubMed ID: 7796709
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dosage-dependent antifungal efficacy of V-echinocandin (LY303366) against experimental fluconazole-resistant oropharyngeal and esophageal candidiasis.
    Petraitis V; Petraitiene R; Groll AH; Sein T; Schaufele RL; Lyman CA; Francesconi A; Bacher J; Piscitelli SC; Walsh TJ
    Antimicrob Agents Chemother; 2001 Feb; 45(2):471-9. PubMed ID: 11158743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oropharyngeal and esophageal candidiasis in immunocompromised patients: treatment issues.
    Darouiche RO
    Clin Infect Dis; 1998 Feb; 26(2):259-72; quiz 273-4. PubMed ID: 9502438
    [No Abstract]   [Full Text] [Related]  

  • 7. Pharmacokinetics of fluconazole in saliva and plasma after administration of an oral suspension and capsules.
    Koks CH; Meenhorst PL; Hillebrand MJ; Bult A; Beijnen JH
    Antimicrob Agents Chemother; 1996 Aug; 40(8):1935-7. PubMed ID: 8843308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective study of fluconazole suspension for the treatment of oesophageal candidiasis in patients with AIDS.
    Laine L; Rabeneck L
    Aliment Pharmacol Ther; 1995 Oct; 9(5):553-6. PubMed ID: 8580277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Itraconazole and fluconazole in oropharyngeal candidiasis.
    van der Bijl P; Arendorf TM
    Ann Dent; 1993; 52(2):12-6. PubMed ID: 8267372
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation between in vitro and in vivo antifungal activities in experimental fluconazole-resistant oropharyngeal and esophageal candidiasis.
    Walsh TJ; Gonzalez CE; Piscitelli S; Bacher JD; Peter J; Torres R; Shetti D; Katsov V; Kligys K; Lyman CA
    J Clin Microbiol; 2000 Jun; 38(6):2369-73. PubMed ID: 10835005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oropharyngeal candidiasis in patients with AIDS: randomized comparison of fluconazole versus nystatin oral suspensions.
    Pons V; Greenspan D; Lozada-Nur F; McPhail L; Gallant JE; Tunkel A; Johnson CC; McCarty J; Panzer H; Levenstein M; Barranco A; Green S
    Clin Infect Dis; 1997 Jun; 24(6):1204-7. PubMed ID: 9195083
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison of fluconazole oral suspension and amphotericin B oral suspension in older patients with oropharyngeal candidosis. Multicentre Study Group.
    Taillandier J; Esnault Y; Alemanni M
    Age Ageing; 2000 Mar; 29(2):117-23. PubMed ID: 10791445
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical case presentations. Oropharyngeal and esophageal candidiasis in HIV disease.
    AIDS Patient Care STDS; 1997 Feb; 11 Suppl 1():S22-5. PubMed ID: 11361748
    [No Abstract]   [Full Text] [Related]  

  • 14. Clinical pharmacokinetics of fluconazole in superficial and systemic mycoses.
    Debruyne D
    Clin Pharmacokinet; 1997 Jul; 33(1):52-77. PubMed ID: 9250423
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fluconazole versus itraconazole in therapy of oropharyngeal candidiasis in cancer patients: a prospective comparative randomized trial.
    Studena V; Sycova Z; Helpianska L; Sorkovska D; Pichna P; Lacka J; Hlavacova E; Oravcova E; Krcmery V; Studena M
    J Chemother; 1995 Nov; 7 Suppl 4():204-5. PubMed ID: 8904157
    [No Abstract]   [Full Text] [Related]  

  • 16. Efficacy of fluconazole in the treatment of upper gastrointestinal candidiasis in neutropenic patients with cancer: factors influencing the outcome.
    Akova M; Akalin HE; Uzun O; Hayran M; Tekuzman G; Kansu E; Aslan S; Telatar H
    Clin Infect Dis; 1994 Mar; 18(3):298-304. PubMed ID: 8011807
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fluconazole for the treatment of candidiasis: 15 years experience.
    Cha R; Sobel JD
    Expert Rev Anti Infect Ther; 2004 Jun; 2(3):357-66. PubMed ID: 15482201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rationalizing prescribing for oral and oesophageal candidiasis.
    Taylor CB; Finlay R; Richardson C; Bunting P; Welch J
    Int J STD AIDS; 1996 Oct; 7(6):452. PubMed ID: 8940678
    [No Abstract]   [Full Text] [Related]  

  • 19. Fluconazole in the management of oropharyngeal candidosis in a predominantly HIV antibody-positive group of patients.
    Dupont B; Drouhet E
    J Med Vet Mycol; 1988 Feb; 26(1):67-71. PubMed ID: 2837559
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Itraconazole suspension in the treatment of HIV-infected patients with fluconazole-resistant oropharyngeal candidiasis and esophagitis].
    Eichel M; Just-Nübling G; Helm EB; Stille W
    Mycoses; 1996; 39 Suppl 1():102-6. PubMed ID: 8767280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.